Cnot7-null mice exhibit high bone mass phenotype and modulation of BMP actions

Journal of Bone and Mineral Research

Volumn 22, Issue 8, 2007, Pages 1217-1223

  Washio Oikawa, Kaoru ^a   Nakamura, Takahisa ^b   Usui, Michihiko ^a   Yoneda, Mitsuhiro ^b   Ezura, Youichi ^a   Ishikawa, Isao ^a   Nakashima, Kazuhisa ^a   Noda, Tetsuo ^c   Yamamoto, Tadashi ^b   Noda, Masaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b The Universtiry of Tokyo   (Japan)

^c CANCER INSTITUTE   (Japan)

Author keywords

Alkaline phosphatase; BMP; CCR4 associated factor 1; CCR4 NOT complex 7; Osteoblasts

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; PROTEIN CNOT7; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; CNOT7 PROTEIN, MOUSE; PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MASS; CALVARIA; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PHENOTYPE; PROTEIN BINDING; ANIMAL; BONE; BONE DENSITY; C57BL MOUSE; CELL CULTURE; DRUG EFFECT; GENETICS; HISTOLOGY; METABOLISM; MOUSE MUTANT;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; CELLS, CULTURED; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 34548059480     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.070411     Document Type: Article

References (37)

1. 1 Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw‐Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309–319.
2. 2 Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T 1997 Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89: 755–764.
3. 3 Manolagas SC 2000 Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21: 115–137.
4. 4 Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR, Selby PB, Owen MJ 1997 Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89: 765–771.
5. 5 Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B 2002 The novel zinc finger‐containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108: 17–29.
6. 6 Takayanagi H, Sato K, Takaoka A, Taniguchi T 2005 Interplay between interferon and other cytokine systems in bone metabolism. Immunol Rev 208: 181–193.
7. 7 Wan M, Cao X 2005 BMP signaling in skeletal development. Biochem Biophys Res Commun 328: 651–657.
8. 8 Heldin CH, Miyazono K, ten Dijke P 1997 TGF‐beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390: 465–471.
9. 9 Ryoo HM, Lee MH, Kim YJ 2006 Critical molecular switches involved in BMP‐2‐induced osteogenic differentiation of mesenchymal cells. Gene 366: 51–57.
10. 10 Ohyama Y, Nifuji A, Maeda Y, Amagasa T, Noda M 2004 Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis. Endocrinology 145: 4685–4692.
11. 11 Brunet LJ, McMahon JA, McMahon AP, Harland RM 1998 Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. Science 280: 1455–1457.
12. 12 Piccolo S, Sasai Y, Lu B, De Robertis EM 1996 Dorsoventral patterning in Xenopus: Inhibition of ventral signals by direct binding of chordin to BMP‐4. Cell 86: 589–598.
13. 13 Hemmati‐Brivanlou A, Kelly OG, Melton DA 1994 Follistatin, an antagonist of activin, is expressed in the Spemann organizer and displays direct neuralizing activity. Cell 77: 283–295.
14. 14 Canalis E, Economides AN, Gazzerro E 2003 Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24: 218–235.
15. 15 Yoshida Y, Tanaka S, Umemori H, Minowa O, Usui M, Ikematsu N, Hosoda E, Imamura T, Kuno J, Yamashita T, Miyazono K, Noda M, Noda T, Yamamoto T 2000 Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell 103: 1085–1097.
16. 16 Yanagita M 2005 BMP antagonists: Their roles in development and involvement in pathophysiology. Cytokine Growth Factor Rev 16: 309–317.
17. 17 McMahon JA, Takada S, Zimmerman LB, Fan CM, Harland RM, McMahon AP 1998 Noggin‐mediated antagonism of BMP signaling is required for growth and patterning of the neural tube and somite. Genes Dev 12: 1438–1452.
18. 18 Devlin RD, Du Z, Pereira RC, Kimble RB, Economides AN, Jorgetti V, Canalis E 2003 Skeletal overexpression of noggin results in osteopenia and reduced bone formation. Endocrinology 144: 1972–1978.
19. 19 Draper MP, Salvadore C, Denis CL 1995 Identification of a mouse protein whose homolog in Saccharomyces cerevisiae is a component of the CCR4 transcriptional regulatory complex. Mol Cell Biol 15: 3487–3495.
20. 20 Tucker M, Valencia‐Sanchez MA, Staples RR, Chen J, Denis CL, Parker R 2001 The transcription factor associated Ccr4 and Caf1 proteins are components of the major cytoplasmic mRNA deadenylase in Saccharomyces cerevisiae. Cell 104: 377–386.
21. 21 Yoshida Y, Hosoda E, Nakamura T, Yamamoto T 2001 Association of ANA, a member of the antiproliferative Tob family proteins, with a Caf1 component of the CCR4 transcriptional regulatory complex. Jpn J Cancer Res 92: 592–596.
22. 22 Prevot D, Morel AP, Voeltzel T, Rostan MC, Rimokh R, Magaud JP, Corbo L 2001 Relationships of the antiproliferative proteins BTG1 and BTG2 with CAF1, the human homolog of a component of the yeast CCR4 transcriptional complex: Involvement in estrogen receptor alpha signaling pathway. J Biol Chem 276: 9640–9648.
23. 23 Ikematsu N, Yoshida Y, Kawamura‐Tsuzuku J, Ohsugi M, Onda M, Hirai M, Fujimoto J, Yamamoto T 1999 Tob2, a novel anti‐proliferative Tob/BTG1 family member, associates with a component of the CCR4 transcriptional regulatory complex capable of binding cyclin‐dependent kinases. Oncogene 18: 7432–7441.
24. 24 Bogdan JA, Adams‐Burton C, Pedicord DL, Sukovich DA, Benfield PA, Corjay MH, Stoltenborg JK, Dicker IB 1998 Human carbon catabolite repressor protein (CCR4)‐associative factor 1: Cloning, expression and characterization of its interaction with the B‐cell translocation protein BTG1. Biochem J 336: 471–481.
25. 25 Nakamura T, Yao R, Ogawa T, Suzuki T, Ito C, Tsunekawa N, Inoue K, Ajima R, Miyasaka T, Yoshida Y, Ogura A, Toshimori K, Noce T, Yamamoto T, Noda T 2004 Oligo‐astheno‐teratozoospermia in mice lacking Cnot7, a regulator of retinoid X receptor beta. Nat Genet 36: 528–533.
26. 26 Berthet C, Morera AM, Asensio MJ, Chauvin MA, Morel AP, Dijoud F, Magaud JP, Durand P, Rouault JP 2004 CCR4‐associated factor CAF1 is an essential factor for spermatogenesis. Mol Cell Biol 24: 5808–5820.
27. 27 Ogawa T, Ito C, Nakamura T, Tamura Y, Yamamoto T, Noda T, Kubota Y, Toshimori K 2004 Abnormal sperm morphology caused by defects in Sertoli cells of Cnot7 knockout mice. Arch Histol Cytol 67: 307–314.
28. 28 Washio‐Oikawa K, Nakamura T, Usui M, Yoneda M, Ezura Y, Ishikawa I, Nakashima K, Yamamoto T, Noda M 2006 Expression analysis of LacZ gene placed in the locus of Cnot7 exhibits its activity in osteoblasts in vivo and in mineralized nodules in vitro. J Cell Biochem 99: 538–544.
29. 29 Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595–610.
30. 30 Noda M, Camilliere JJ 1989 In vivo stimulation of bone formation by transforming growth factor‐beta. Endocrinology 124: 2991–2994.
31. 31 Usui M, Yoshida Y, Yamashita T, Tsuji K, Isao I, Yamamoto T, Nifuji A, Noda M 2002 Enhancing effect of Tob deficiency on bone formation is specific to bone morphogenetic protein‐induced osteogenesis. J Bone Miner Res 17: 1026–1033.
32. 32 Dickman S 1998 Growing joints use their noggins. Science 280: 1350.
33. 33 Yoshida Y, von Bubnoff A, Ikematsu N, Blitz IL, Tsuzuku JK, Yoshida EH, Umemori H, Miyazono K, Yamamoto T, Cho KW 2003 Tob proteins enhance inhibitory Smad‐receptor interactions to repress BMP signaling. Mech Dev 120: 629–637.
34. 34 Yoshida Y, Nakamura T, Komoda M, Satoh H, Suzuki T, Tsuzuku JK, Miyasaka T, Yoshida EH, Umemori H, Kunisaki RK, Tani K, Ishii S, Mori S, Suganuma M, Noda T, Yamamoto T 2003 Mice lacking a transcriptional corepressor Tob are predisposed to cancer. Genes Dev 17: 1201–1206.
35. 35 Leib ES 2005 Treatment of low bone mass in premenopausal women: When may it be appropriate? Curr Osteoporos Rep 3: 13–18.
36. 36 Kitahara K, Ishijima M, Rittling SR, Tsuji K, Kurosawa H, Nifuji A, Denhardt DT, Noda M 2003 Osteopontin deficiency induces parathyroid hormone enhancement of cortical bone formation. Endocrinology 144: 2132–2140.
37. 37 Deal C 2004 The use of intermittent human parathyroid hormone as a treatment for osteoporosis. Curr Rheumatol Rep 6: 49–58.